ADMA

Adma Biologics closed at $11.24, up 1.49%, outperforming the S&P 500's 0.28% gain. The stock has gained 16.47% over the past month.

Projected EPS of $0.19 represents an 18.75% increase year-over-year, with revenue expected at $139.8 million (+4.16% YoY). For the full fiscal year, earnings are projected at $0.78 per share (+30%) and revenue at $536.82 million (+5.22%). ADMA holds a Zacks Rank #3 (Hold) with a Forward P/E of 14.25, trading at a discount to its industry average of 25.

Adma Biologics (ADMA) outperformed the broader market on October 8, 2026, rising 1.87% to $10.33 while the S&P 500 declined 0.47%. The infectious disease drug developer has gained 7.3% over the past month and is expected to report EPS of $0.19 (up 18.75% YoY) with revenue of $139.8 million (up 4.16% YoY). The company trades at a Forward P/E of 13.06, a discount to its industry average of 23.26, and currently holds a Zacks Rank of #3 (Hold).

ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY).

However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score.

Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses.